A Human Ex Vivo Skin Model to Study Candida auris Biofilms

Dora E Corzo-León; Catherine Mark; Donna M MacCallum; Carol A Munro

doi:10.1007/978-1-0716-2417-3_21

A Human Ex Vivo Skin Model to Study Candida auris Biofilms

Dora E Corzo-León, Catherine Mark, Donna M MacCallum, Carol A Munro

Instituto Nacional de Enfermedades Respiratorias, Unidad de Epidemiología Hospitalaria e Infectologia

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Candida auris can persist for long periods on hospital surfaces and on the skin. C. auris has the ability to form drug-resistant biofilms, which can substantially impact on patient outcome. In comparison to Candida albicans, C. auris has a lower capacity to form biofilms in in vitro models and a higher capacity when tested on animal skin models. Intraspecies variation is shown to exist, with some clinical isolates having greater biofilm capabilities than others. There is a need for models that closely mimic the real niches where infection occurs on human patients. This protocol describes, in detail, a human skin model to study C. auris biofilm formation using catheterized and non-catheterized skin.

Original language	English
Pages (from-to)	259-267
Number of pages	9
Journal	Methods in molecular biology (Clifton, N.J.)
Volume	2517
DOIs	https://doi.org/10.1007/978-1-0716-2417-3_21
Publication status	Published - 9 Jun 2022

Bibliographical note

Acknowledgments
This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377) and Medical Research Council Centre for Medical Mycology (MR/N006364/1), previously at the University of Aberdeen, now at the University of Exeter.

Keywords

Animals
Antifungal Agents/pharmacology
Biofilms
Candida
Candida albicans
Candida auris
Candidiasis/drug therapy
Humans

Access to Document

10.1007/978-1-0716-2417-3_21Licence: Unspecified

Cite this

@article{0ca2b6b523af446e90e89e3f0051660e,

title = "A Human Ex Vivo Skin Model to Study Candida auris Biofilms",

abstract = "Candida auris can persist for long periods on hospital surfaces and on the skin. C. auris has the ability to form drug-resistant biofilms, which can substantially impact on patient outcome. In comparison to Candida albicans, C. auris has a lower capacity to form biofilms in in vitro models and a higher capacity when tested on animal skin models. Intraspecies variation is shown to exist, with some clinical isolates having greater biofilm capabilities than others. There is a need for models that closely mimic the real niches where infection occurs on human patients. This protocol describes, in detail, a human skin model to study C. auris biofilm formation using catheterized and non-catheterized skin.",

keywords = "Animals, Antifungal Agents/pharmacology, Biofilms, Candida, Candida albicans, Candida auris, Candidiasis/drug therapy, Humans",

author = "Corzo-Le{\'o}n, {Dora E} and Catherine Mark and MacCallum, {Donna M} and Munro, {Carol A}",

note = "Acknowledgments This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377) and Medical Research Council Centre for Medical Mycology (MR/N006364/1), previously at the University of Aberdeen, now at the University of Exeter.",

year = "2022",

month = jun,

day = "9",

doi = "10.1007/978-1-0716-2417-3_21",

language = "English",

volume = "2517",

pages = "259--267",

journal = "Methods in molecular biology (Clifton, N.J.)",

issn = "1064-3745",

publisher = "Humana Press",

}

TY - JOUR

T1 - A Human Ex Vivo Skin Model to Study Candida auris Biofilms

AU - Corzo-León, Dora E

AU - Mark, Catherine

AU - MacCallum, Donna M

AU - Munro, Carol A

N1 - Acknowledgments This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377) and Medical Research Council Centre for Medical Mycology (MR/N006364/1), previously at the University of Aberdeen, now at the University of Exeter.

PY - 2022/6/9

Y1 - 2022/6/9

N2 - Candida auris can persist for long periods on hospital surfaces and on the skin. C. auris has the ability to form drug-resistant biofilms, which can substantially impact on patient outcome. In comparison to Candida albicans, C. auris has a lower capacity to form biofilms in in vitro models and a higher capacity when tested on animal skin models. Intraspecies variation is shown to exist, with some clinical isolates having greater biofilm capabilities than others. There is a need for models that closely mimic the real niches where infection occurs on human patients. This protocol describes, in detail, a human skin model to study C. auris biofilm formation using catheterized and non-catheterized skin.

AB - Candida auris can persist for long periods on hospital surfaces and on the skin. C. auris has the ability to form drug-resistant biofilms, which can substantially impact on patient outcome. In comparison to Candida albicans, C. auris has a lower capacity to form biofilms in in vitro models and a higher capacity when tested on animal skin models. Intraspecies variation is shown to exist, with some clinical isolates having greater biofilm capabilities than others. There is a need for models that closely mimic the real niches where infection occurs on human patients. This protocol describes, in detail, a human skin model to study C. auris biofilm formation using catheterized and non-catheterized skin.

KW - Animals

KW - Antifungal Agents/pharmacology

KW - Biofilms

KW - Candida

KW - Candida albicans

KW - Candida auris

KW - Candidiasis/drug therapy

KW - Humans

U2 - 10.1007/978-1-0716-2417-3_21

DO - 10.1007/978-1-0716-2417-3_21

M3 - Article

C2 - 35674961

SN - 1064-3745

VL - 2517

SP - 259

EP - 267

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

ER -

A Human Ex Vivo Skin Model to Study Candida auris Biofilms

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this